You are viewing content intended for a different location. This may affect your ability to shop online.

Our systems are now restored following recent technical disruption, and we’re working hard to catch up on publishing. We apologise for the inconvenience caused. Find out more

Recommended product

Popular links

Popular links


Innovation versus Financialization in the US Pharmaceutical Industry

Innovation versus Financialization in the US Pharmaceutical Industry

Innovation versus Financialization in the US Pharmaceutical Industry

Authors:
Öner Tulum, The Academic-Industry Research Network
William Lazonick, The Academic-Industry Research Network
Published:
November 2025
Availability:
Available
Format:
Paperback
ISBN:
9781009707985

Looking for an examination copy?

If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact collegesales@cambridge.org providing details of the course you are teaching.

    Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.

    Product details

    • Published: November 2025
    • Format: Adobe eBook Reader
    • ISBN: 9781009708036
    • Length: 75 pages
    • Dimensions: 229 × 152 mm
    • Availability: This ISBN is for an eBook version which is distributed on our behalf by a third party.

    Table of Contents

    • 1. High drug prices and the inflation reduction act of 2022
    • 2. What is a 'Fair' drug price?
    • 3. Foundational, translational, and clinical research
    • 4. Collective and cumulative learning in translational research
    • 5. The knowledge ecosystem of drug discovery and development, and the fair price for a drug
    • References.

    Authors

    Öner Tulum , The Academic-Industry Research Network

    William Lazonick , The Academic-Industry Research Network

    • Table of contents navigation
    • Latest accessibility assessment date: 2025-09-19